UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a ...

A new drug-free, minimally invasive intervention targets the root cause of progressive loss of neural function in spinal ...

The FDA has approved the sBLA for once every 4 weeks lecanemab-irmb (Leqembi®) intravenous maintenance dosing.

Recall matters when it comes to medical content. Find out how knowledge can be better retained through interactive medical ...